Compare Global Payments Inc (GPN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Global Payments Inc trades at $80.89 (market cap $21.67B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Global Payments Inc is far larger — about 4.3× Travere Therapeutics Inc. Common Stock's market cap, and Global Payments Inc pays a 1.22% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GPN | TVTX | |
|---|---|---|
Market Cap | $21.67B | $5.02B |
Volume | 1,851,678 | 2,060,842 |
Sector | Financials | Health |
52-Week High | $94.83 | $67.52 |
52-Week Low | $62.47 | $26.79 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $39.81B | $5.15B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $81.88, down 0.22% on the day, with a neutral technical signal despite bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2026 projections indicate potential profitability challenges. Recent developments include the Genius platform rollout and Worldpay integration, driving optimism about future growth. Valuation metrics show a P/E of 38.81 and P/S of 2.05, with analysts maintaining a consensus price target of $102.75.
GPN presents a mixed outlook with strong operational execution offset by near-term profitability concerns. The stock offers 25% upside to consensus targets based on digital payment growth initiatives, but faces risks from rising costs, competitive pressures, and projected negative net margins in 2026. Institutional ownership trends remain positive with recent position increases by major banks.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
